Skip to content

menu

Securities litigation and enforcement logo
HomeAboutResourcesContact
Search
Close
Class actionsCross border issuesSecurities regulatory decisionsWhite collar crime
View topics Archives
Subscribe

Securities litigation and enforcement

limitation period

Subscribe to limitation period via RSS

Re Fauth: A Primer on ss. 75(1)(a), 92(4.1) and 93(b) of Alberta’s Securities Act

Photo of Steven Leitl, QCPhoto of Aditya Badami
By Steven Leitl, QC & Aditya Badami on November 21, 2018

The Alberta Securities Commission (ASC) recently released its decision in the matter of Re Fauth, finding the respondent, Vernon Ray Fauth (Fauth), in breach of ss. 75(1)(a), 92(4.1) and 93(b) of Alberta’s Securities Act…

The Horror Show Continues: Application of the Limitation Period in s. 138.14 of the Ontario Securities Act in Kaynes v BP, PLC

Posted on September 14, 2017

In Kaynes v. BP, P.L.C. [2017] ONSC 5172, Justice Perell characterizes his decision about the operation of the limitation period set out in s. 138.14 of Part XXIII.1 of the Ontario Securities Act (the Act) as “the latest…

Subscribe to Securities litigation and enforcement

Subscribe to this publication

Securities litigation and enforcement

Facebook Twitter RSS LinkedIn YouTube
Published by
Norton Rose Fulbright LLP logo
DisclaimerPrivacy policy

About

In this blog, litigators from Norton Rose Fulbright offices in both Canada and the United States comment upon domestic developments in securities litigation in both countries and cross border issues. Among other things, we deliver insights on recent securities law decisions, amendments to securities statutes and regulations, securities class actions and cross border developments. We have broad experience and international expertise in these matters and are frequently called upon for advice in high-profile securities litigation, enforcement proceedings and internal investigations. Stay connected with Securities litigation and enforcement and subscribe to the blog today.

Read more

Topics

Archives

Copyright © 2025, Norton Rose Fulbright LLP. All rights reserved.